DOCSLIB.ORG

Download the PDF Here

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

Table S1. Analyzed genes FC: fold change; sign.: significantly changed Gene FC sign. FC sign. FC sign. Symbol Ensembl ID pre-diab vs C pre-diab. vs C T2DM vs C T2DM vs C t52 vs t0 t52 vs t0 MARCH2 ENSG00000099785 1.00 no 1.17 yes 1.00 no SEPT3 ENSG00000100167 1.00 no 1.00 no 1.00 no A2BP1 ENSG00000078328 1.00 no 1.00 no 1.00 no AAAS ENSG00000094914 1.00 no 1.00 no 1.00 no AACS ENSG00000081760 1.00 no 0.88 yes 1.14 yes AARS ENSG00000090861 1.00 no 1.00 no 1.00 no AASS ENSG00000008311 0.92 no 1.00 no 0.94 no ABCA7 ENSG00000064687 1.00 no 1.00 no 1.00 no ABCB1 ENSG00000085563 0.92 no 1.00 no 1.00 no ABCB11 ENSG00000073734 1.00 no 1.00 no 1.00 no ABCB4 ENSG00000005471 0.91 no 1.00 no 1.00 no ABCB5 ENSG00000004846 0.94 no 1.00 no 0.93 no ABCC2 ENSG00000023839 0.96 no 1.00 no 1.00 no ABCC6 ENSG00000091262 0.92 no 0.89 no 0.95 no ABCC8 ENSG00000006071 1.00 no 1.00 no 1.00 no ABCC9 ENSG00000069431 1.00 no 1.00 no 1.00 no ABCD1 ENSG00000101986 1.00 no 1.00 no 1.00 no ABCF2 ENSG00000033050 1.00 no 1.00 no 1.00 no ABHD12 ENSG00000100997 1.00 no 1.00 no 1.00 no ABHD14A ENSG00000042022 1.00 no 1.00 no 1.00 no ABHD4 ENSG00000100439 1.11 yes 1.13 yes 0.93 no ABHD5 ENSG00000011198 1.00 no 1.00 no 1.00 no ABL1 ENSG00000097007 1.10 yes 1.00 no 1.00 no ABLIM1 ENSG00000099204 1.00 no 1.00 no 0.78 yes ABP1 ENSG00000002726 0.93 no 1.00 no 1.00 no ACAA1 ENSG00000060971 1.00 no 1.00 no 1.00 no ACACB ENSG00000076555 1.00 no 1.00 no 1.00 no ACADVL ENSG00000072778 1.24 yes 1.14 yes 1.00 no ACAT1 ENSG00000075239 1.00 no 1.00 no 1.00 no ACCN4 ENSG00000072182 1.00 no 1.00 no 1.00 no ACCN5 ENSG00000023843 0.93 no 1.00 no 0.94 no ACD ENSG00000102977 1.00 no 1.00 no 0.95 no ACHE ENSG00000087085 1.00 no 1.00 no 1.00 no ACIN1 ENSG00000100813 1.00 no 1.00 no 1.00 no ACO2 ENSG00000100412 1.00 no 0.84 yes 1.13 yes ACOT7 ENSG00000097021 1.00 no 1.00 no 1.00 no ACOT8 ENSG00000101473 1.00 no 1.00 no 0.93 no A COX3 ENSG00000087008 0.91 yes 1.00 no 1.00 no ACP5 ENSG00000102575 0.95 no 1.00 no 1.00 no ACPP ENSG00000014257 1.00 no 1.08 no 1.00 no ACSBG1 ENSG00000103740 1.00 no 1.00 no 0.97 no ACSL4 ENSG00000068366 1.00 no 0.88 no 1.13 no ACSM3 ENSG00000005187 1.00 no 1.00 no 0.93 no ACTB ENSG00000075624 0.78 yes 1.00 no 1.00 no ACTL6B ENSG00000077080 1.00 no 1.00 no 1.00 no ACTN1 ENSG00000072110 1.00 no 1.00 no 1.00 no ACTN2 ENSG00000077522 1.00 no 1.00 no 1.00 no ACTR5 ENSG00000101442 1.00 no 1.00 no 1.00 no ACTR6 ENSG00000075089 1.00 no 1.00 no 1.00 no ADAM11 ENSG00000073670 1.00 no 1.00 no 1.00 no 2 ADAM22 ENSG00000008277 0.93 no 1.00 no 0.95 no ADAM28 ENSG00000042980 0.95 no 1.00 no 1.00 no ADAM7 ENSG00000069206 0.94 no 1.00 no 1.00 no ADAMTS2 ENSG00000087116 1.00 no 1.00 no 1.00 no ADAMTS6 ENSG00000049192 1.00 no 1.00 no 1.00 no ADAT1 ENSG00000065457 1.00 no 1.00 no 1.07 no ADCK1 ENSG00000063761 1.00 no 1.00 no 1.00 no ADCY2 ENSG00000078295 1.00 no 1.00 no 1.00 no ADCYAP1R1ENSG00000078549 0.92 no 1.00 no 1.00 no ADD1 ENSG00000087274 1.00 no 0.95 no 0.95 no ADD2 ENSG00000075340 1.00 no 1.07 no 0.94 no ADIPOR2 ENSG00000006831 1.13 yes 1.00 no 1.00 no ADNP ENSG00000101126 1.00 no 0.94 no 1.00 no ADRB1 ENSG00000043591 1.00 no 1.00 no 0.94 no ADRBK2 ENSG00000100077 0.97 no 1.00 no 1.00 no ADSL ENSG00000100357 0.91 no 0.91 no 1.00 no ADSS ENSG00000035687 1.00 no 1.00 no 1.00 no AFF4 ENSG00000072364 0.97 no 1.00 no 1.00 no AFM ENSG00000079557 0.95 no 1.00 no 1.00 no AFP ENSG00000081051 0.93 no 1.00 no 0.91 no AGA ENSG00000038002 1.00 no 1.10 no 1.00 no AGK ENSG00000006530 1.00 no 0.88 yes 1.08 no AGPAT4 ENSG00000026652 0.95 no 1.00 no 1.00 no AGPS ENSG00000018510 1.00 no 1.00 no 1.00 no AHCY ENSG00000101444 1.00 no 1.00 no 1.00 no AHRR ENSG00000063438 1.00 no 1.00 no 1.07 no AHSA1 ENSG00000100591 1.00 no 0.91 no 1.00 no AIFM2 ENSG00000042286 1.06 no 1.00 no 1.00 no AK2 ENSG00000004455 0.95 no 1.00 no 1.00 no AKAP11 ENSG00000023516 1.00 no 0.94 no 1.00 no AKAP8L ENSG00000011243 1.00 no 1.00 no 0.91 no AKR1B1 ENSG00000085662 1.00 no 1.00 no 1.00 no AKR7A2 ENSG00000053371 1.00 no 0.89 yes 1.00 no ALAS1 ENSG00000023330 1.00 no 0.87 no 1.00 no ALDH18A1 ENSG00000059573 1.00 no 1.06 no 1.00 no ALDH3A2 ENSG00000072210 1.15 yes 1.00 no 1.00 no ALDH3B1 ENSG00000006534 1.00 no 1.00 no 1.00 no ALG13 ENSG00000072319 1.00 no 1.07 no 1.00 no ALG6 ENSG00000088035 1.00 no 1.11 yes 1.00 no ALG9 ENSG00000086848 1.00 no 1.00 no 1.00 no ALKBH1 ENSG00000100601 1.00 no 1.00 no 1.00 no A LOX5 ENSG00000012779 0.90 no 1.00 no 1.00 no ALPK1 ENSG00000073331 1.06 no 1.00 no 1.05 no ALS2 ENSG00000003393 1.00 no 1.00 no 1.00 no ALS2CR2 ENSG00000082146 1.00 no 1.00 no 1.11 yes A LX4 ENSG00000052850 1.00 no 1.00 no 1.00 no AMACR ENSG00000082196 0.91 no 1.00 no 1.00 no AMELY ENSG00000099721 1.00 no 1.00 no 1.00 no AMMECR1 ENSG00000101935 0.97 no 1.00 no 1.00 no AMPH ENSG00000078053 1.00 no 1.00 no 0.90 no ANAPC4 ENSG00000053900 1.00 no 0.94 no 1.00 no ANAPC5 ENSG00000089053 1.00 no 1.00 no 1.00 no ANGEL1 ENSG00000013523 0.96 no 0.94 no 1.00 no ANGPT2 ENSG00000091879 1.00 no 0.93 no 1.04 no 2 ANGPT4 ENSG00000101280 1.00 no 1.00 no 1.00 no ANK1 ENSG00000029534 0.87 yes 1.00 no 1.00 no ANKIB1 ENSG00000001629 1.00 no 1.00 no 1.13 yes ANKRD10 ENSG00000088448 1.00 no 1.00 no 1.00 no ANKRD12 ENSG00000101745 1.00 no 1.00 no 1.00 no ANKRD13A ENSG00000076513 1.00 no 1.00 no 1.00 no ANKRD24 ENSG00000089847 1.00 no 1.00 no 1.00 no ANKRD44 ENSG00000065413 0.96 no 1.00 no 1.00 no ANKRD54 ENSG00000100124 1.06 no 1.00 no 1.00 no ANKS1A ENSG00000064999 0.87 yes 0.83 yes 1.12 yes ANLN ENSG00000011426 0.89 no 1.00 no 1.00 no AOF2 ENSG00000004487 1.00 no 1.00 no 1.00 no AP1B1 ENSG00000100280 1.00 no 1.00 no 1.09 no AP1G2 ENSG00000092051 0.95 no 1.00 no 1.00 no AP1GBP1 ENSG00000006114 0.95 no 1.00 no 0.99 no AP1M1 ENSG00000072958 1.07 no 1.00 no 1.00 no AP2B1 ENSG00000006125 1.00 no 0.95 no 1.00 no AP2S1 ENSG00000042753 1.00 no 1.13 no 1.00 no AP3B2 ENSG00000103723 0.94 no 1.00 no 0.90 no AP3D1 ENSG00000065000 1.00 no 1.00 no 1.00 no AP3M2 ENSG00000070718 1.00 no 1.00 no 1.00 no AP4E1 ENSG00000081014 1.00 no 1.00 no 1.00 no AP4S1 ENSG00000100478 1.00 no 1.00 no 1.04 no APBA2 ENSG00000034053 1.00 no 1.00 no 1.00 no APBA3 ENSG00000011132 1.00 no 0.89 yes 1.07 no APBB1IP ENSG00000077420 0.94 no 1.00 no 1.00 no APEX1 ENSG00000100823 1.00 no 0.94 no 1.11 yes APLP2 ENSG00000084234 1.00 no 1.00 no 1.00 no APOB ENSG00000084674 0.95 no 1.00 no 1.00 no APOH ENSG00000091583 0.93 no 1.00 no 1.06 no APOL1 ENSG00000100342 1.00 no 1.00 no 1.00 no APOL4 ENSG00000100336 1.00 no 1.04 no 0.96 no APPBP2 ENSG00000062725 1.00 no 1.00 no 1.00 no APRIN ENSG00000083642 1.00 no 1.00 no 1.00 no AQP6 ENSG00000086159 1.00 no 1.00 no 1.00 no AQP8 ENSG00000103375 0.95 no 1.00 no 1.00 no AQP9 ENSG00000103569 1.00 no 1.20 no 1.00 no AQR ENSG00000021776 0.95 no 1.00 no 1.00 no ARAF ENSG00000078061 1.00 no 1.00 no 1.00 no ARCN1 ENSG00000095139 1.00 no 1.00 no 1.11 yes ARF5 ENSG00000004059 1.00 no 1.00 no 1.00 no ARFGAP1 ENSG00000101199 1.00 no 1.07 no 1.00 no ARFGAP3 ENSG00000100262 1.00 no 1.00 no 0.91 yes ARFGEF1 ENSG00000066777 1.00 no 1.00 no 1.07 no ARFRP1 ENSG00000101246 1.00 no 1.00 no 1.04 no ARG2 ENSG00000081181 0.62 no 0.73 no 1.00 no ARHGAP10 ENSG00000071205 1.00 no 1.00 no 1.00 no ARHGAP15 ENSG00000075884 1.00 no 1.00 no 1.07 no ARHGAP28 ENSG00000088756 1.00 no 1.00 no 1.00 no ARHGAP4 ENSG00000089820 0.94 no 1.00 no 1.00 no ARHGAP5 ENSG00000100852 1.00 no 1.00 no 1.00 no ARHGAP6 ENSG00000047648 1.00 no 1.00 no 1.00 no ARHGEF1 ENSG00000076928 0.96 no 1.00 no 1.07 no ARHGEF10L ENSG00000074964 1.00 no 1.00 no 1.11 yes 2 ARHGEF5 ENSG00000050327 0.93 no 1.00 no 1.00 no ARHGEF7 ENSG00000102606 1.00 no 1.00 no 1.00 no ARID1B ENSG00000049618 1.00 no 1.00 no 1.00 no ARID4A ENSG00000032219 1.00 no 1.00 no 1.00 no ARID4B ENSG00000054267 1.00 no 1.00 no 1.05 no ARL2BP ENSG00000102931 0.91 no 0.93 no 1.00 no ARMCX3 ENSG00000102401 1.13 yes 1.00 no 1.16 yes ARNTL2 ENSG00000029153 1.00 no 1.00 no 0.92 no ARPC1A ENSG00000013455 1.00 no 1.00 no 1.14 yes ARS2_HUMANENSG00000087087 1.00 no 1.00 no 1.00 no ARSA ENSG00000100299 1.00 no 1.00 no 1.00 no ARSD ENSG00000006756 1.00 no 1.00 no 1.00 no ARSF ENSG00000062096 0.87 no 1.00 no 1.00 no ARVCF ENSG00000099889 1.00 no 1.00 no 1.07 no ARX ENSG00000004848 1.00 no 0.84 yes 1.00 no ASB2 ENSG00000100628 1.00 no 1.00 no 1.00 no ASB4 ENSG00000005981 0.95 no 1.00 no 1.00 no ASB9 ENSG00000102048 1.00 no 1.36 no 1.00 no ASCC2 ENSG00000100325 1.00 no 1.00 no 1.00 no ASIP ENSG00000101440 1.00 no 1.00 no 1.00 no ASNS ENSG00000070669 0.91 no 1.12 no 1.00 no ASPM ENSG00000066279 0.93 no 1.00 no 0.92 no ASTE1 ENSG00000034533 1.00 no 0.91 no 1.00 no ATG16L1 ENSG00000085978 0.95 no 1.00 no 1.00 no ATG4A ENSG00000101844 1.00 no 1.00 no 1.00 no ATG5 ENSG00000057663 1.00 no 1.00 no 1.00 no ATP11A ENSG00000068650 1.00 no 1.00 no 1.00 no ATP11B ENSG00000058063 0.95 no 1.00 no 1.00 no ATP11C ENSG00000101974 0.95 no 1.00 no 1.00 no ATP12A ENSG00000075673 1.00 no 1.00 no 1.00 no ATP1A2 ENSG00000018625 1.00 no 1.00 no 1.05 no ATP1B3 ENSG00000069849 1.00 no 1.00 no 1.00 no ATP1B4 ENSG00000101892 1.00 no 1.00 no 1.00 no ATP2A3 ENSG00000074370 0.95 no 1.00 no 1.00 no ATP2B1 ENSG00000070961 1.00 no 1.00 no 1.00 no ATP2B3 ENSG00000067842 1.00 no 1.00 no 0.93 no ATP2B4 ENSG00000058668 1.00 no 1.00 no 1.11 yes ATP2C1 ENSG00000017260 1.00 no 1.00 no 1.00 no ATP2C2 ENSG00000064270 1.00 no 1.00 no 0.93 no ATP5D ENSG00000099624 0.89 yes 1.00 no 1.00 no ATP6AP1 ENSG00000071553 1.00 no 1.11 yes 0.79 yes ATP6V0A1 ENSG00000033627 1.06 no 1.07 no 0.96 no ATP6V1D ENSG00000100554 1.12 yes 1.00 no 1.17 yes ATP6V1H ENSG00000047249 1.00 no 1.00 no 0.89 yes ATP8B4
Recommended publications
  • Genome-Wide Characterization of PRE-1 Reveals a Hidden Evolutionary Relationship Between Suidae and Primates

    Genome-Wide Characterization of PRE-1 Reveals a Hidden Evolutionary Relationship Between Suidae and Primates

    bioRxiv preprint doi: https://doi.org/10.1101/025791; this version posted August 31, 2015. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Genome-wide characterization of PRE-1 reveals a hidden evolutionary relationship between suidae and primates Hao Yu1,, Qingyan Wu1, Jing Zhag1, Ying zhang1, Chao Lu1, Yunyun Cheng1, Zhihui Zhao1, Andreas Windemuth3, Di Liu2,, Linlin Hao1 1 College of Animal Science, Jilin University, Changchun 130062, China 2 Heilongjiang Academy of Agricultural Sciences, Harbin 150086, China 3 Abcam, Firefly BioWorks Inc, United States Corresponding author: Linlin Hao ([email protected]); Di liu ([email protected]); Andreas Windemuth ([email protected]) Abstract We identified and characterized a free PRE-1 element inserted into the promoter region of the porcine IGFBP7 gene whose integration mechanisms into the genome, including copy number, distribution preferences, capacity to exonize and phyloclustering pattern are similar to that of the primate Alu element. 98% of these PRE-1 elements also contain two conserved internal AluI restriction enzyme recognition sites, and the RNA structure of PRE1 can be folded into a two arms model like the Alu RNA structure. It is more surprising that the length of the PRE-1 fragments is nearly the same in 20 chromosomes and positively correlated to its fracture site frequency. All of these fracture sites are close to the mutation hot spots of PRE-1 families, and most of these hot spots are located in the non-complementary fragile regions of the PRE-1 RNA structure.
  • 1 Evidence for Gliadin Antibodies As Causative Agents in Schizophrenia

    1 Evidence for Gliadin Antibodies As Causative Agents in Schizophrenia

    1 Evidence for gliadin antibodies as causative agents in schizophrenia. C.J.Carter PolygenicPathways, 20 Upper Maze Hill, Saint-Leonard’s on Sea, East Sussex, TN37 0LG [email protected] Tel: 0044 (0)1424 422201 I have no fax Abstract Antibodies to gliadin, a component of gluten, have frequently been reported in schizophrenia patients, and in some cases remission has been noted following the instigation of a gluten free diet. Gliadin is a highly immunogenic protein, and B cell epitopes along its entire immunogenic length are homologous to the products of numerous proteins relevant to schizophrenia (p = 0.012 to 3e-25). These include members of the DISC1 interactome, of glutamate, dopamine and neuregulin signalling networks, and of pathways involved in plasticity, dendritic growth or myelination. Antibodies to gliadin are likely to cross react with these key proteins, as has already been observed with synapsin 1 and calreticulin. Gliadin may thus be a causative agent in schizophrenia, under certain genetic and immunological conditions, producing its effects via antibody mediated knockdown of multiple proteins relevant to the disease process. Because of such homology, an autoimmune response may be sustained by the human antigens that resemble gliadin itself, a scenario supported by many reports of immune activation both in the brain and in lymphocytes in schizophrenia. Gluten free diets and removal of such antibodies may be of therapeutic benefit in certain cases of schizophrenia. 2 Introduction A number of studies from China, Norway, and the USA have reported the presence of gliadin antibodies in schizophrenia 1-5. Gliadin is a component of gluten, intolerance to which is implicated in coeliac disease 6.
  • The Title of the Article

    The Title of the Article

    Mechanism-Anchored Profiling Derived from Epigenetic Networks Predicts Outcome in Acute Lymphoblastic Leukemia Xinan Yang, PhD1, Yong Huang, MD1, James L Chen, MD1, Jianming Xie, MSc2, Xiao Sun, PhD2, Yves A Lussier, MD1,3,4§ 1Center for Biomedical Informatics and Section of Genetic Medicine, Department of Medicine, The University of Chicago, Chicago, IL 60637 USA 2State Key Laboratory of Bioelectronics, Southeast University, 210096 Nanjing, P.R.China 3The University of Chicago Cancer Research Center, and The Ludwig Center for Metastasis Research, The University of Chicago, Chicago, IL 60637 USA 4The Institute for Genomics and Systems Biology, and the Computational Institute, The University of Chicago, Chicago, IL 60637 USA §Corresponding author Email addresses: XY: [email protected] YH: [email protected] JC: [email protected] JX: [email protected] XS: [email protected] YL: [email protected] - 1 - Abstract Background Current outcome predictors based on “molecular profiling” rely on gene lists selected without consideration for their molecular mechanisms. This study was designed to demonstrate that we could learn about genes related to a specific mechanism and further use this knowledge to predict outcome in patients – a paradigm shift towards accurate “mechanism-anchored profiling”. We propose a novel algorithm, PGnet, which predicts a tripartite mechanism-anchored network associated to epigenetic regulation consisting of phenotypes, genes and mechanisms. Genes termed as GEMs in this network meet all of the following criteria: (i) they are co-expressed with genes known to be involved in the biological mechanism of interest, (ii) they are also differentially expressed between distinct phenotypes relevant to the study, and (iii) as a biomodule, genes correlate with both the mechanism and the phenotype.
  • An Order Estimation Based Approach to Identify Response Genes

    An Order Estimation Based Approach to Identify Response Genes

    AN ORDER ESTIMATION BASED APPROACH TO IDENTIFY RESPONSE GENES FOR MICRO ARRAY TIME COURSE DATA A Thesis Presented to The Faculty of Graduate Studies of The University of Guelph by ZHIHENG LU In partial fulfilment of requirements for the degree of Doctor of Philosophy September, 2008 © Zhiheng Lu, 2008 Library and Bibliotheque et 1*1 Archives Canada Archives Canada Published Heritage Direction du Branch Patrimoine de I'edition 395 Wellington Street 395, rue Wellington Ottawa ON K1A0N4 Ottawa ON K1A0N4 Canada Canada Your file Votre reference ISBN: 978-0-494-47605-5 Our file Notre reference ISBN: 978-0-494-47605-5 NOTICE: AVIS: The author has granted a non­ L'auteur a accorde une licence non exclusive exclusive license allowing Library permettant a la Bibliotheque et Archives and Archives Canada to reproduce, Canada de reproduire, publier, archiver, publish, archive, preserve, conserve, sauvegarder, conserver, transmettre au public communicate to the public by par telecommunication ou par Plntemet, prefer, telecommunication or on the Internet, distribuer et vendre des theses partout dans loan, distribute and sell theses le monde, a des fins commerciales ou autres, worldwide, for commercial or non­ sur support microforme, papier, electronique commercial purposes, in microform, et/ou autres formats. paper, electronic and/or any other formats. The author retains copyright L'auteur conserve la propriete du droit d'auteur ownership and moral rights in et des droits moraux qui protege cette these. this thesis. Neither the thesis Ni la these ni des extraits substantiels de nor substantial extracts from it celle-ci ne doivent etre imprimes ou autrement may be printed or otherwise reproduits sans son autorisation.
  • A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    A Computational Approach for Defining a Signature of Β-Cell Golgi Stress in Diabetes Mellitus

    Page 1 of 781 Diabetes A Computational Approach for Defining a Signature of β-Cell Golgi Stress in Diabetes Mellitus Robert N. Bone1,6,7, Olufunmilola Oyebamiji2, Sayali Talware2, Sharmila Selvaraj2, Preethi Krishnan3,6, Farooq Syed1,6,7, Huanmei Wu2, Carmella Evans-Molina 1,3,4,5,6,7,8* Departments of 1Pediatrics, 3Medicine, 4Anatomy, Cell Biology & Physiology, 5Biochemistry & Molecular Biology, the 6Center for Diabetes & Metabolic Diseases, and the 7Herman B. Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN 46202; 2Department of BioHealth Informatics, Indiana University-Purdue University Indianapolis, Indianapolis, IN, 46202; 8Roudebush VA Medical Center, Indianapolis, IN 46202. *Corresponding Author(s): Carmella Evans-Molina, MD, PhD ([email protected]) Indiana University School of Medicine, 635 Barnhill Drive, MS 2031A, Indianapolis, IN 46202, Telephone: (317) 274-4145, Fax (317) 274-4107 Running Title: Golgi Stress Response in Diabetes Word Count: 4358 Number of Figures: 6 Keywords: Golgi apparatus stress, Islets, β cell, Type 1 diabetes, Type 2 diabetes 1 Diabetes Publish Ahead of Print, published online August 20, 2020 Diabetes Page 2 of 781 ABSTRACT The Golgi apparatus (GA) is an important site of insulin processing and granule maturation, but whether GA organelle dysfunction and GA stress are present in the diabetic β-cell has not been tested. We utilized an informatics-based approach to develop a transcriptional signature of β-cell GA stress using existing RNA sequencing and microarray datasets generated using human islets from donors with diabetes and islets where type 1(T1D) and type 2 diabetes (T2D) had been modeled ex vivo. To narrow our results to GA-specific genes, we applied a filter set of 1,030 genes accepted as GA associated.
  • Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS

    Protein Identities in Evs Isolated from U87-MG GBM Cells As Determined by NG LC-MS/MS

    Protein identities in EVs isolated from U87-MG GBM cells as determined by NG LC-MS/MS. No. Accession Description Σ Coverage Σ# Proteins Σ# Unique Peptides Σ# Peptides Σ# PSMs # AAs MW [kDa] calc. pI 1 A8MS94 Putative golgin subfamily A member 2-like protein 5 OS=Homo sapiens PE=5 SV=2 - [GG2L5_HUMAN] 100 1 1 7 88 110 12,03704523 5,681152344 2 P60660 Myosin light polypeptide 6 OS=Homo sapiens GN=MYL6 PE=1 SV=2 - [MYL6_HUMAN] 100 3 5 17 173 151 16,91913397 4,652832031 3 Q6ZYL4 General transcription factor IIH subunit 5 OS=Homo sapiens GN=GTF2H5 PE=1 SV=1 - [TF2H5_HUMAN] 98,59 1 1 4 13 71 8,048185945 4,652832031 4 P60709 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 - [ACTB_HUMAN] 97,6 5 5 35 917 375 41,70973209 5,478027344 5 P13489 Ribonuclease inhibitor OS=Homo sapiens GN=RNH1 PE=1 SV=2 - [RINI_HUMAN] 96,75 1 12 37 173 461 49,94108966 4,817871094 6 P09382 Galectin-1 OS=Homo sapiens GN=LGALS1 PE=1 SV=2 - [LEG1_HUMAN] 96,3 1 7 14 283 135 14,70620005 5,503417969 7 P60174 Triosephosphate isomerase OS=Homo sapiens GN=TPI1 PE=1 SV=3 - [TPIS_HUMAN] 95,1 3 16 25 375 286 30,77169764 5,922363281 8 P04406 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 - [G3P_HUMAN] 94,63 2 13 31 509 335 36,03039959 8,455566406 9 Q15185 Prostaglandin E synthase 3 OS=Homo sapiens GN=PTGES3 PE=1 SV=1 - [TEBP_HUMAN] 93,13 1 5 12 74 160 18,68541938 4,538574219 10 P09417 Dihydropteridine reductase OS=Homo sapiens GN=QDPR PE=1 SV=2 - [DHPR_HUMAN] 93,03 1 1 17 69 244 25,77302971 7,371582031 11 P01911 HLA class II histocompatibility antigen,
  • Tepzz¥ 6Z54za T

    Tepzz¥ 6Z54za T

    (19) TZZ¥ ZZ_T (11) EP 3 260 540 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 27.12.2017 Bulletin 2017/52 C12N 15/113 (2010.01) A61K 9/127 (2006.01) A61K 31/713 (2006.01) C12Q 1/68 (2006.01) (21) Application number: 17000579.7 (22) Date of filing: 12.11.2011 (84) Designated Contracting States: • Sarma, Kavitha AL AT BE BG CH CY CZ DE DK EE ES FI FR GB Philadelphia, PA 19146 (US) GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO • Borowsky, Mark PL PT RO RS SE SI SK SM TR Needham, MA 02494 (US) • Ohsumi, Toshiro Kendrick (30) Priority: 12.11.2010 US 412862 P Cambridge, MA 02141 (US) 20.12.2010 US 201061425174 P 28.07.2011 US 201161512754 P (74) Representative: Clegg, Richard Ian et al Mewburn Ellis LLP (62) Document number(s) of the earlier application(s) in City Tower accordance with Art. 76 EPC: 40 Basinghall Street 11840099.3 / 2 638 163 London EC2V 5DE (GB) (71) Applicant: The General Hospital Corporation Remarks: Boston, MA 02114 (US) •Thecomplete document including Reference Tables and the Sequence Listing can be downloaded from (72) Inventors: the EPO website • Lee, Jeannie T •This application was filed on 05-04-2017 as a Boston, MA 02114 (US) divisional application to the application mentioned • Zhao, Jing under INID code 62. San Diego, CA 92122 (US) •Claims filed after the date of receipt of the divisional application (Rule 68(4) EPC). (54) POLYCOMB-ASSOCIATED NON-CODING RNAS (57) This invention relates to long non-coding RNAs (IncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting IncRNAs.
  • | Hai Lala at Matalamitaka Huoleht I

    | Hai Lala at Matalamitaka Huoleht I

    |HAI LALA AT MATALAMITAKAUS009816096B2 HUOLEHT I (12 ) United States Patent (10 ) Patent No. : US 9 ,816 , 096 B2 Heintz et al. (45 ) Date of Patent: Nov . 14 , 2017 ( 54 ) METHODS AND COMPOSITIONS FOR 6 , 143 , 566 A 11/ 2000 Heintz et al. TRANSLATIONAL PROFILING AND 6 , 156 , 574 A 12 / 2000 Heintz et al. 6 , 252 , 130 B1 6 / 2001 Federoff MOLECULAR PHENOTYPING 6 , 270, 969 B1 8 / 2001 Hartley et al. 6 , 403 ,374 B1 6 / 2002 Tsien et al. (71 ) Applicant: THE ROCKEFELLER 6 , 410 , 317 B1 6 /2002 Farmer UNIVERSITY , New York , NY (US ) 6 , 441 , 269 B1 8 / 2002 Serafini et al . 6 , 485 , 912 B1 11/ 2002 Heintz et al. @ 6 , 495 , 318 B2 12 / 2002 Harney ( 72 ) Inventors: Nathaniel Heintz , Pelham Manor, NY 6 ,635 ,422 B2 10 / 2003 Keene et al. (US ) ; Paul Greengard , New York , NY 6 , 821, 759 B1 11/ 2004 Heintz et al . (US ) ; Myriam Heiman , New York , NY 7 , 098, 031 B2B2 8 /2006 Choulika et al . (US ) ; Anne Schaefer , New York , NY 7 ,297 ,482 B2 11 /2007 Anderson et al . (US ) ; Joseph P . Doyle , New York , NY 7 , 393 , 632 B2 7 / 2008 Cheo et al. 2003 /0119104 A1 6 /2003 Perkins et al . (US ) ; Joseph D . Dougherty , St. Louis , 2004 / 0023256 A1 2 / 2004 Puglisi et al . MO (US ) 2005 / 0009028 Al 1 /2005 Heintz et al. 2006 /0183147 AL 8 /2006 Meyer - Franke (73 ) Assignee : THE ROCKEFELLER 2011/ 0314565 Al 12 /2011 Heintz et al . UNIVERSITY , New York , NY (US ) FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 EP 1132479 A1 9 / 2001 WO WO -01 / 48480 A1 7 /2001 U .
  • Download The

    Download The

    PROBING THE INTERACTION OF ASPERGILLUS FUMIGATUS CONIDIA AND HUMAN AIRWAY EPITHELIAL CELLS BY TRANSCRIPTIONAL PROFILING IN BOTH SPECIES by POL GOMEZ B.Sc., The University of British Columbia, 2002 A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF MASTER OF SCIENCE in THE FACULTY OF GRADUATE STUDIES (Experimental Medicine) THE UNIVERSITY OF BRITISH COLUMBIA (Vancouver) January 2010 © Pol Gomez, 2010 ABSTRACT The cells of the airway epithelium play critical roles in host defense to inhaled irritants, and in asthma pathogenesis. These cells are constantly exposed to environmental factors, including the conidia of the ubiquitous mould Aspergillus fumigatus, which are small enough to reach the alveoli. A. fumigatus is associated with a spectrum of diseases ranging from asthma and allergic bronchopulmonary aspergillosis to aspergilloma and invasive aspergillosis. Airway epithelial cells have been shown to internalize A. fumigatus conidia in vitro, but the implications of this process for pathogenesis remain unclear. We have developed a cell culture model for this interaction using the human bronchial epithelium cell line 16HBE and a transgenic A. fumigatus strain expressing green fluorescent protein (GFP). Immunofluorescent staining and nystatin protection assays indicated that cells internalized upwards of 50% of bound conidia. Using fluorescence-activated cell sorting (FACS), cells directly interacting with conidia and cells not associated with any conidia were sorted into separate samples, with an overall accuracy of 75%. Genome-wide transcriptional profiling using microarrays revealed significant responses of 16HBE cells and conidia to each other. Significant changes in gene expression were identified between cells and conidia incubated alone versus together, as well as between GFP positive and negative sorted cells.
  • Differential Patterns of Allelic Loss in Estrogen Receptor-Positive Infiltrating Lobular and Ductal Breast Cancer

    Differential Patterns of Allelic Loss in Estrogen Receptor-Positive Infiltrating Lobular and Ductal Breast Cancer

    GENES, CHROMOSOMES & CANCER 47:1049–1066 (2008) Differential Patterns of Allelic Loss in Estrogen Receptor-Positive Infiltrating Lobular and Ductal Breast Cancer L. W. M. Loo,1 C. Ton,1,2 Y.-W. Wang,2 D. I. Grove,2 H. Bouzek,1 N. Vartanian,1 M.-G. Lin,1 X. Yuan,1 T. L. Lawton,3 J. R. Daling,2 K. E. Malone,2 C. I. Li,2 L. Hsu,2 and P.L. Porter1,2,3* 1Division of Human Biology,Fred Hutchinson Cancer Research Center,Seattle,WA 2Division of Public Health Sciences,Fred Hutchinson Cancer Research Center,Seattle,WA 3Departmentof Pathology,Universityof Washington,Seattle,WA The two main histological types of infiltrating breast cancer, lobular (ILC) and the more common ductal (IDC) carcinoma are morphologically and clinically distinct. To assess the molecular alterations associated with these breast cancer subtypes, we conducted a whole-genome study of 166 archival estrogen receptor (ER)-positive tumors (89 IDC and 77 ILC) using the Affy- metrix GeneChip® Mapping 10K Array to identify sites of loss of heterozygosity (LOH) that either distinguished, or were shared by, the two phenotypes. We found single nucleotide polymorphisms (SNPs) of high-frequency LOH (>50%) common to both ILC and IDC tumors predominately in 11q, 16q, and 17p. Overall, IDC had a slightly higher frequency of LOH events across the genome than ILC (fractional allelic loss 5 0.186 and 0.156). By comparing the average frequency of LOH by chro- mosomal arm, we found IDC tumors with significantly (P < 0.05) higher frequency of LOH on 3p, 5q, 8p, 9p, 20p, and 20q than ILC tumors.
  • Targeting PH Domain Proteins for Cancer Therapy

    Targeting PH Domain Proteins for Cancer Therapy

    The Texas Medical Center Library DigitalCommons@TMC The University of Texas MD Anderson Cancer Center UTHealth Graduate School of The University of Texas MD Anderson Cancer Biomedical Sciences Dissertations and Theses Center UTHealth Graduate School of (Open Access) Biomedical Sciences 12-2018 Targeting PH domain proteins for cancer therapy Zhi Tan Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations Part of the Bioinformatics Commons, Medicinal Chemistry and Pharmaceutics Commons, Neoplasms Commons, and the Pharmacology Commons Recommended Citation Tan, Zhi, "Targeting PH domain proteins for cancer therapy" (2018). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access). 910. https://digitalcommons.library.tmc.edu/utgsbs_dissertations/910 This Dissertation (PhD) is brought to you for free and open access by the The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences at DigitalCommons@TMC. It has been accepted for inclusion in The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Dissertations and Theses (Open Access) by an authorized administrator of DigitalCommons@TMC. For more information, please contact [email protected]. TARGETING PH DOMAIN PROTEINS FOR CANCER THERAPY by Zhi Tan Approval page APPROVED: _____________________________________________ Advisory Professor, Shuxing Zhang, Ph.D. _____________________________________________
  • Supplementary Materials

    Supplementary Materials

    Supplementary materials Supplementary Table S1: MGNC compound library Ingredien Molecule Caco- Mol ID MW AlogP OB (%) BBB DL FASA- HL t Name Name 2 shengdi MOL012254 campesterol 400.8 7.63 37.58 1.34 0.98 0.7 0.21 20.2 shengdi MOL000519 coniferin 314.4 3.16 31.11 0.42 -0.2 0.3 0.27 74.6 beta- shengdi MOL000359 414.8 8.08 36.91 1.32 0.99 0.8 0.23 20.2 sitosterol pachymic shengdi MOL000289 528.9 6.54 33.63 0.1 -0.6 0.8 0 9.27 acid Poricoic acid shengdi MOL000291 484.7 5.64 30.52 -0.08 -0.9 0.8 0 8.67 B Chrysanthem shengdi MOL004492 585 8.24 38.72 0.51 -1 0.6 0.3 17.5 axanthin 20- shengdi MOL011455 Hexadecano 418.6 1.91 32.7 -0.24 -0.4 0.7 0.29 104 ylingenol huanglian MOL001454 berberine 336.4 3.45 36.86 1.24 0.57 0.8 0.19 6.57 huanglian MOL013352 Obacunone 454.6 2.68 43.29 0.01 -0.4 0.8 0.31 -13 huanglian MOL002894 berberrubine 322.4 3.2 35.74 1.07 0.17 0.7 0.24 6.46 huanglian MOL002897 epiberberine 336.4 3.45 43.09 1.17 0.4 0.8 0.19 6.1 huanglian MOL002903 (R)-Canadine 339.4 3.4 55.37 1.04 0.57 0.8 0.2 6.41 huanglian MOL002904 Berlambine 351.4 2.49 36.68 0.97 0.17 0.8 0.28 7.33 Corchorosid huanglian MOL002907 404.6 1.34 105 -0.91 -1.3 0.8 0.29 6.68 e A_qt Magnogrand huanglian MOL000622 266.4 1.18 63.71 0.02 -0.2 0.2 0.3 3.17 iolide huanglian MOL000762 Palmidin A 510.5 4.52 35.36 -0.38 -1.5 0.7 0.39 33.2 huanglian MOL000785 palmatine 352.4 3.65 64.6 1.33 0.37 0.7 0.13 2.25 huanglian MOL000098 quercetin 302.3 1.5 46.43 0.05 -0.8 0.3 0.38 14.4 huanglian MOL001458 coptisine 320.3 3.25 30.67 1.21 0.32 0.9 0.26 9.33 huanglian MOL002668 Worenine